CJC-1295 DAC in Anabolic-Signaling Research: Reference

CJC-1295 DAC, an advanced growth hormone-releasing hormone (GHRH) analog, is extensively studied in anabolic-signaling research due to its unique mechanism involving extended albumin binding via a Drug Affinity Complex. This compound provides a valuable tool for investigators exploring hormonal regulation of growth and metabolism in controlled laboratory environments.

Current scientific literature, as evidenced by one indexed PubMed publication, focuses on its biochemical characteristics and potential in diverse research models, underscoring the need for further dedicated investigations into its properties and effects. To date, there are no registered studies on ClinicalTrials.gov, highlighting its current status as a compound primarily for fundamental scientific inquiry rather than clinical application.

Understanding CJC-1295 DAC: Chemical Structure and Properties

CJC-1295 DAC represents a sophisticated synthetic peptide designed to emulate the actions of growth hormone-releasing hormone (GHRH), a naturally occurring hypothalamic peptide. Its primary innovation lies in its unique conjugation with a Drug Affinity Complex (DAC), a strategic modification intended to significantly prolong its circulating half-life. This design principle differentiates CJC-1295 DAC from earlier GHRH analogs by enhancing its stability and duration of action within research models, thereby facilitating sustained release of growth hormone (GH) and subsequent insulin-like growth factor 1 (IGF-1).

The core structure of CJC-1295 DAC is a modified GHRH analog, specifically a GHRH(1-29) fragment. This 29-amino acid sequence is highly potent and retains the essential biological activity of natural GHRH by binding to and activating the GHRH receptor. However, native GHRH and its unmodified 1-29 fragment are rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) and exhibit a very short plasma half-life, typically only a few minutes. To overcome this limitation, CJC-1295 DAC incorporates a specialized modification: a lysine residue at the 2-position, which renders it resistant to DPP-IV enzymatic cleavage. This initial modification significantly improves its intrinsic stability compared to unmodified GHRH.

The most distinctive feature of CJC-1295 DAC is the covalent attachment of the Drug Affinity Complex (DAC). This complex is typically an acyl moiety, such as maleimidopropionic acid, which forms a stable bond with serum albumin. Albumin, being the most abundant protein in plasma, acts as a circulating reservoir for the peptide. By reversibly binding to albumin, CJC-1295 DAC is protected from rapid enzymatic degradation and renal clearance. This albumin-binding strategy effectively increases the peptide’s hydrodynamic radius and extends its systemic residence time, allowing for a sustained and pulsatile release profile of growth hormone over an extended period in various research contexts.

Physicochemical Characteristics Relevant to Research

Molecular Weight: The specific molecular weight varies slightly depending on the exact synthesis and counter-ion, but it is generally in the range suitable for peptide analysis. Researchers should refer to the specific batch’s Certificate of Analysis (CoA) for precise values.
Purity: High purity is paramount for accurate research outcomes. Analytical methods such as High-Performance Liquid Chromatography (HPLC) are routinely employed to ensure the peptide’s purity, typically exceeding 98%. Impurities, if present, can confound experimental results, underscoring the importance of sourcing from reputable suppliers.
Solubility and Stability: CJC-1295 DAC is typically soluble in sterile water or dilute acidic solutions. Its stability in solution and during storage is critical for maintaining its activity. Proper storage and handling conditions, such as refrigeration or freezing in lyophilized form and protection from light, are essential to prevent degradation and preserve its structural integrity and biological potency over time.

Mechanism of Action: Prolonged GHRH Receptor Agonism and Albumin Binding

The biological activity of CJC-1295 DAC is primarily mediated through its role as a potent and selective agonist of the growth hormone-releasing hormone receptor (GHRHR). The GHRHR is a G protein-coupled receptor (GPCR) predominantly expressed on somatotroph cells within the anterior pituitary gland. Upon binding of GHRH or its analogs, the GHRHR undergoes a conformational change, leading to the activation of intracellular signaling cascades. This activation is the critical initial step in the physiological regulation of growth hormone synthesis and secretion.

Specifically, activation of the GHRHR by CJC-1295 DAC leads to the stimulation of adenylate cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP levels subsequently activate protein kinase A (PKA). PKA, in turn, phosphorylates various downstream targets, including transcription factors such as cAMP response element-binding protein (CREB). This signaling pathway ultimately upregulates the transcription of the GH gene, leading to increased synthesis of GH, and also promotes the exocytosis of pre-formed GH secretory granules, resulting in its pulsatile release into the bloodstream. This direct stimulation of pituitary somatotrophs is central to its utility in anabolic-signaling research.

The defining characteristic that distinguishes CJC-1295 DAC from other GHRH analogs is its unique “Drug Affinity Complex” (DAC) technology. This covalent modification is key to its prolonged action. The DAC moiety, typically comprising a maleimidopropionic acid linked to a reactive group, facilitates a reversible, non-covalent binding interaction with endogenous circulating albumin. Albumin, with its long half-life of approximately 19 days in humans, acts as a carrier protein, forming a transient complex with CJC-1295 DAC. This binding significantly reduces the rate at which the peptide is metabolized by proteases or cleared by the kidneys, effectively extending its systemic residence time and improving its pharmacokinetic profile.

The extended albumin binding capacity allows CJC-1295 DAC to maintain a relatively constant circulating concentration of active peptide over an extended period, which translates into sustained GHRHR activation. This prolonged agonism results in a more consistent and physiological pattern of GH release compared to short-acting GHRH analogs, which require frequent administration. The sustained release of GH subsequently drives the hepatic production and release of insulin-like growth factor 1 (IGF-1), another critical anabolic mediator. This mechanism is central to understanding CJC-1295 DAC’s potential in research exploring sustained anabolic signaling pathways. Further details on this mechanism can be found on the CJC-1295 DAC Mechanism of Action page.

Analytical Methodologies for CJC-1295 DAC Research

Robust analytical methodologies are indispensable for any research involving synthetic peptides like CJC-1295 DAC. These methods are critical for confirming the identity, assessing the purity, quantifying the concentration, and evaluating the stability of the peptide both in its raw form and within complex biological matrices. The integrity of research findings is directly dependent on the accuracy and reliability of these analytical data, ensuring that observed biological effects can be confidently attributed to the peptide under investigation. Royal Peptide Labs emphasizes stringent quality testing protocols to support reliable research.

Prior to conducting any biological experiments, thorough characterization of the research peptide is essential. High-Performance Liquid Chromatography (HPLC) coupled with ultraviolet (UV) detection is a standard technique for assessing the purity of CJC-1295 DAC. Reverse-phase HPLC (RP-HPLC) is particularly effective for separating the peptide from impurities, truncated sequences, or oxidized forms based on their hydrophobicity. The chromatogram provides a purity profile, with the main peak representing CJC-1295 DAC and minor peaks indicating impurities. Mass Spectrometry (MS), often coupled with liquid chromatography (LC-MS or LC-MS/MS), is crucial for confirming the molecular weight and amino acid sequence. This powerful combination allows for precise identification of the peptide, detection of potential modifications, and verification of its structural integrity. Nuclear Magnetic Resonance (NMR) spectroscopy can further provide detailed structural information, particularly useful for confirming the presence and linkage of the DAC moiety.

For quantitative analysis of CJC-1295 DAC in biological samples (e.g., cell culture media, animal plasma, tissue homogenates), highly sensitive and specific methods are required. LC-MS/MS is the gold standard for pharmacokinetic and pharmacodynamic studies due to its unparalleled sensitivity and selectivity, enabling accurate measurement of peptide concentrations even at picomolar levels. This is vital for characterizing absorption, distribution, metabolism, and excretion (ADME) profiles in preclinical models. Enzyme-Linked Immunosorbent Assays (ELISA) or Radioimmunoassays (RIA), while potentially less precise for exact structural confirmation, can be developed for high-throughput quantification of the peptide in biological matrices, provided that highly specific antibodies are available and validated. These assays are particularly useful for measuring peptide levels over time in various research models.

Key Analytical Considerations for CJC-1295 DAC

Identity Confirmation: Use LC-MS/MS to verify the exact molecular weight and characteristic fragmentation pattern, confirming the presence of both the GHRH analog and the DAC modification. NMR can provide additional structural details.
Purity Assessment: RP-HPLC with UV detection to ensure the peptide is free from significant impurities, truncations, or byproducts. A high purity percentage (typically >98%) is critical for accurate research.
Quantitative Analysis: LC-MS/MS for precise measurement of CJC-1295 DAC concentrations in biological samples, essential for pharmacokinetic studies and dose-response curve generation. ELISA/RIA may be suitable for screening or high-throughput if validated.
Stability Testing: Conduct accelerated and long-term stability studies using HPLC and MS to monitor degradation products under various storage conditions, informing appropriate storage and handling guidelines to maintain peptide integrity.
Batch-to-Batch Consistency: Regular analysis of different batches ensures reproducibility across research experiments. A comprehensive Certificate of Analysis (CoA) should accompany each batch, detailing purity, identity, and other critical parameters.

CJC-1295 DAC in Anabolic-Signaling Research Models: In Vitro Applications

In vitro research models provide a controlled environment to dissect the cellular and molecular mechanisms by which CJC-1295 DAC influences anabolic signaling pathways. These studies are fundamental for understanding the peptide’s direct effects on target cells, elucidating receptor interactions, and identifying downstream cascades without the complexities of systemic physiological responses. Given the overarching goal of investigating anabolic signaling, a primary focus of in vitro studies is often on cell types relevant to muscle, bone, and metabolic tissues, or directly on pituitary cells that produce growth hormone.

A crucial starting point for in vitro investigations involves pituitary cell lines, such as GH3 or AtT-20 cells, which serve as established models for studying growth hormone secretion. In these cell lines, researchers can directly assess CJC-1295 DAC’s ability to stimulate GHRH receptor activation, measure intracellular cAMP accumulation, and quantify GH release. For instance, treatment of pituitary somatotrophs with CJC-1295 DAC would be expected to increase cAMP levels, activate PKA, and ultimately enhance GH synthesis and secretion, mirroring its in vivo role. This allows for detailed dose-response analyses and investigations into the kinetics of GHRH receptor agonism, differentiating it from shorter-acting GHRH analogs.

Beyond pituitary models, research extends to peripheral cell types that are responsive to GH and IGF-1, the ultimate effectors of anabolic signaling. For example, myoblast cell lines (e.g., C2C12, L6) are invaluable for studying muscle anabolism. In these models, CJC-1295 DAC, indirectly through IGF-1 (or directly in some contexts where GHRHRs might be expressed), could be explored for its effects on cell proliferation, differentiation into myotubes, and protein synthesis rates. Similarly, osteoblast cell lines (e.g., MC3T3-E1) can be utilized to investigate its impact on bone formation markers, mineralized nodule formation, and gene expression related to osteogenesis. Adipocyte cell lines may also be used to explore potential lipolytic effects or alterations in metabolic signaling.

Key In Vitro Methodologies and Endpoints

Receptor Binding Assays: Radioligand binding studies or competitive binding assays using fluorescently labeled peptides to determine CJC-1295 DAC’s affinity for the GHRH receptor.
Intracellular Signaling Pathway Analysis: Measurement of cAMP levels (e.g., using FRET-based assays), PKA activation (e.g., by assessing phosphorylation of specific substrates), and activation of MAPK/ERK pathways via Western blot analysis of phosphorylated proteins.
Growth Hormone (GH) Secretion: ELISA or RIA to quantify GH released into the cell culture supernatant from pituitary cell lines, providing a direct measure of agonist efficacy.
IGF-1 Production: While primarily hepatic in vivo, some peripheral cells can produce IGF-1 locally. ELISA or Western blot for IGF-1 levels in cell lysates or media can indicate local paracrine/autocrine effects.
Cell Proliferation and Viability Assays: Techniques like MTT, WST-1, or BrdU incorporation assays to evaluate the impact of CJC-1295 DAC on cell growth and survival in various cell lines.
Differentiation Assays: For myoblasts, assessing fusion index and expression of myogenic markers (e.g., MyoD, Myogenin) by RT-qPCR or Western blot. For osteoblasts, measuring alkaline phosphatase activity and calcium deposition.
Gene Expression Analysis: RT-qPCR or RNA-Seq to profile changes in the expression of genes involved in anabolic processes, protein synthesis, cell growth, and metabolism.
Protein Synthesis Rates: Metabolic labeling techniques (e.g., SUnSET assay using puromycin, or incorporation of labeled amino acids) to directly quantify protein synthesis in treated cells.

CJC-1295 DAC in Anabolic-Signaling Research Models: In Vivo Considerations

Transitioning from in vitro to in vivo models introduces the complexities of systemic physiology, allowing researchers to explore the integrated effects of CJC-1295 DAC on anabolic signaling within a whole organism. Preclinical animal models, primarily rodents, are indispensable for understanding pharmacokinetics, pharmacodynamics, tissue distribution, and overall biological impact. These studies provide crucial insights into how sustained GHRH receptor agonism translates into tangible physiological changes related to growth, metabolism, and body composition. It is imperative to adhere strictly to ethical guidelines for animal research, such as those set by Institutional Animal Care and Use Committees (IACUCs).

Pharmacokinetic (PK) studies in animal models are paramount for characterizing CJC-1295 DAC’s behavior within the living system. Due to its DAC moiety, the peptide is expected to exhibit a significantly prolonged half-life compared to unmodified GHRH or shorter-acting analogs. Researchers typically administer CJC-1295 DAC via subcutaneous injection and collect blood samples at various time points to quantify plasma concentrations using highly sensitive analytical methods like LC-MS/MS. This allows for the determination of key PK parameters such as absorption rate, maximum concentration (Cmax), time to Cmax (Tmax), elimination half-life (t½), and area under the curve (AUC). These data are critical for establishing appropriate dosing regimens and frequencies in subsequent in vivo studies. The sustained exposure provided by the DAC modification is a key research area, distinguishing its profile from conventional peptides.

Pharmacodynamic (PD) studies directly assess the biological responses to CJC-1295 DAC administration. The primary PD endpoint is the measurement of circulating growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. In animal models, regular administration of CJC-1295 DAC is expected to lead to sustained elevations in both GH and IGF-1, reflecting the prolonged GHRHR agonism. This sustained elevation can then be correlated with downstream anabolic effects on target tissues. Beyond systemic hormone levels, researchers investigate tissue-specific outcomes in muscle, bone, and adipose tissue. For instance, muscle mass, muscle fiber type distribution, and protein content can be assessed. Bone mineral density, bone strength, and markers of bone turnover can be examined. Changes in body composition, such as lean mass and fat mass, are also critical endpoints for anabolic research.

Key In Vivo Research Considerations

Animal Model Selection: Commonly mice or rats due to their well-characterized physiology, genetic tractability, and cost-effectiveness. The choice of strain, age, and sex can significantly influence outcomes and should be carefully justified.
Dosing Regimen: Based on PK data, researchers determine optimal doses and frequency of administration (e.g., daily, weekly, bi-weekly) to achieve sustained therapeutic-like levels of GH/IGF-1 without inducing receptor desensitization.
Routes of Administration: Typically subcutaneous injection due to its ease and suitability for peptide delivery. Intraperitoneal or intravenous routes might be used for specific experimental designs.
Biomarker Monitoring: Regular collection of blood, urine, or tissue samples for quantifying GH, IGF-1, IGFBP-3, and other relevant anabolic or metabolic markers using ELISA, RIA, or multiplex assays.
Tissue Histology and Morphometry: Microscopic examination of muscle, bone, and other tissues to assess cellular changes, fiber size, bone architecture, and tissue remodeling.
Functional Assessments: In some models, functional tests (e.g., grip strength, treadmill performance) might be used to evaluate physiological improvements related to anabolic effects.
Safety and Tolerability: Monitoring animal health, body weight, food intake, and general behavior for any adverse reactions, although CJC-1295 DAC is generally well-tolerated in preclinical models.
Ethical Approval: All in vivo studies must be conducted under strict adherence to ethical guidelines and approved by an Institutional Animal Care and Use Committee (IACUC) or equivalent body.

Comparative Research: CJC-1295 DAC vs. Other GHRH Analogs

Comparative research is vital for positioning CJC-1295 DAC within the broader landscape of growth hormone-releasing hormone (GHRH) analogs. By contrasting its properties and effects with those of other established or investigational peptides, researchers can fully appreciate its unique attributes, particularly its prolonged duration of action. This comparative approach helps delineate the specific advantages offered by the Drug Affinity Complex (DAC) technology and informs the selection of appropriate GHRH analogs for various research questions.

The most fundamental comparison for CJC-1295 DAC is with native human GHRH itself. Endogenous GHRH is a 44-amino acid peptide that, while potent, has an extremely short circulating half-life, primarily due to rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and other peptidases. In research, this necessitates continuous infusion or very frequent bolus injections to maintain physiological levels, which can be impractical for chronic studies. CJC-1295 DAC, with its DPP-IV resistant modification and albumin-binding DAC moiety, bypasses these limitations, offering a sustained agonism of the GHRH receptor with less frequent administration. This extended action is a significant differentiator, allowing for more stable GH/IGF-1 elevation over time in research models.

Another critical comparison is with CJC-1295 without DAC, sometimes referred to as Sermorelin (though Sermorelin is technically GHRH 1-29 amide and CJC-1295 without DAC is a modified GHRH 1-29). CJC-1295 (without DAC) is a tetrasubstituted GHRH analog (Tyr-D-Ala-Asp-Ala) that is resistant to DPP-IV enzymatic degradation. While this modification significantly improves its half-life compared to native GHRH (extending it to around 30 minutes), it still lacks the profound half-life extension conferred by the DAC moiety. Research comparing CJC-1295 DAC to CJC-1295 (without DAC) consistently demonstrates that the DAC-conjugated version exhibits a substantially longer plasma half-life (e.g., several days versus minutes to hours) and a more sustained elevation of GH and IGF-1 in animal models. This extended duration of action makes CJC-1295 DAC particularly attractive for studies requiring chronic, stable elevation of the GH-IGF-1 axis with minimal intervention.

Further comparative research may involve other GHRH mimetics or GH secretagogues. For instance, peptides like Hexarelin or GHRP-2 act via the ghrelin receptor (GHSR-1a) to stimulate GH release through a different mechanism, primarily by inhibiting somatostatin and directly stimulating GH release. While both GHRH analogs and ghrelin mimetics increase GH, their mechanisms and pulsatility profiles can differ significantly. Research studies can investigate whether combining CJC-1295 DAC with ghrelin mimetics leads to synergistic effects on GH release or anabolic signaling. These comparative analyses are crucial for researchers to select the most appropriate peptide for their specific experimental

Frequently Asked Questions

What is CJC-1295 DAC and how does it function in a research context?

CJC-1295 DAC is a synthetic growth hormone-releasing hormone (GHRH) analog modified with a Drug Affinity Complex (DAC), which facilitates reversible binding to albumin. In research, this modification is studied for its ability to extend the compound’s half-life, thereby providing a sustained GHRH receptor agonist effect in experimental models. Researchers investigate this prolonged activity to understand its impact on GHRH-mediated signaling pathways over extended periods.

How does the DAC modification distinguish CJC-1295 DAC from non-DAC GHRH analogs in research?

The DAC modification in CJC-1295 DAC is designed to create a covalent bond with circulating albumin, which significantly extends its circulation half-life compared to GHRH analogs without this modification. In research, this means that a single administration in an experimental model can lead to a more sustained GHRH receptor activation, allowing for studies on prolonged hormonal influences without frequent re-dosing. This characteristic is particularly relevant for chronic research models exploring long-term cellular or physiological responses.

What analytical techniques are crucial for characterizing CJC-1295 DAC in research?

For comprehensive characterization of CJC-1295 DAC in a research setting, several analytical techniques are crucial. High-Performance Liquid Chromatography (HPLC) coupled with UV detection or Mass Spectrometry (LC-MS/MS) is essential for purity assessment, quantification, and identification. Peptide sequencing (e.g., Edman degradation or tandem MS) can confirm the amino acid sequence. Circular Dichroism (CD) spectroscopy may be used to study secondary structure, while stability studies employing forced degradation (heat, light, pH) analyzed by chromatographic methods are vital to understand its integrity over time. Binding assays (e.g., surface plasmon resonance) can also be employed to investigate its affinity for albumin and GHRH receptors *in vitro*.

What types of in vitro models are relevant for studying CJC-1295 DAC’s effects on anabolic signaling?

*In vitro* research models are crucial for dissecting the cellular mechanisms of CJC-1295 DAC. Relevant models include primary pituitary cell cultures or established somatotroph cell lines (e.g., GH3 cells) to study GHRH receptor binding, downstream signaling (e.g., cAMP production, intracellular calcium mobilization), and growth hormone secretion. Skeletal muscle cell lines (e.g., C2C12 myoblasts) or adipocyte precursor cell lines can also be utilized to investigate secondary effects on cell proliferation, differentiation, and metabolic pathways, providing insights into its potential influence on anabolic processes at a cellular level.

What are the primary considerations for conducting in vivo research with CJC-1295 DAC?

*In vivo* research with CJC-1295 DAC requires careful consideration of appropriate experimental models, dosing regimens, and monitoring parameters. Researchers typically use rodent models (e.g., rats, mice) or larger animal models to investigate pharmacokinetic profiles, pharmacodynamic effects on growth hormone secretion, and potential impacts on body composition or metabolic markers. Key considerations include selecting an appropriate species, determining a dose range based on *in vitro* data and comparative pharmacology, establishing ethical protocols, and monitoring for physiological changes, organ function, and potential off-target effects, all within a strictly controlled research environment.

How does the limited publication record (one PubMed publication, zero clinical trials) impact the current research understanding of CJC-1295 DAC?

The limited publication record, specifically one indexed PubMed publication and zero registered clinical trials, indicates that CJC-1295 DAC is in a very early stage of scientific investigation. This means that a comprehensive understanding of its precise biochemical characteristics, full spectrum of pharmacological effects, long-term stability, and potential interactions in complex biological systems is still nascent. Researchers must rely heavily on fundamental principles of peptide chemistry and GHRH pharmacology, as well as extrapolation from related compounds, while acknowledging the need for significant original research to establish a robust scientific foundation for CJC-1295 DAC.

What ethical guidelines should researchers follow when working with CJC-1295 DAC?

When conducting research with CJC-1295 DAC, researchers must adhere to stringent ethical guidelines, particularly when employing *in vivo* animal models. This includes obtaining approval from Institutional Animal Care and Use Committees (IACUC) or equivalent bodies, ensuring humane treatment of research subjects, minimizing discomfort, and justifying the necessity of animal use. All handling and disposal of the compound must comply with laboratory safety protocols and local regulations for research chemicals, emphasizing responsible conduct of research and avoiding misuse.

Where can researchers access high-quality CJC-1295 DAC for their studies?

Researchers seeking high-quality CJC-1295 DAC for their studies should source it from reputable chemical suppliers or peptide synthesis laboratories that specialize in providing compounds exclusively for research purposes. It is crucial to ensure that the supplier provides appropriate documentation, such as Certificates of Analysis (CoA), verifying the identity, purity, and concentration of the compound. Royal Peptide Labs, for instance, offers CJC-1295 DAC strictly for laboratory and research use only, emphasizing its commitment to supplying materials suitable for rigorous scientific investigation.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.